.jpg)
1 hour ago
3
Article content
LJUBLJANA, Slovenia — Cosylab and Heron Neutron Medical Corp. announced today, 10 June 2026, the signing of a Letter of Intent to establish a strategic framework for joint market development to support the global deployment of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
The collaboration aims to accelerate the development and integration of sophisticated software solutions for use with AB-BNCT while strengthening AB-BNCT’s international market access and business development. By combining Cosylab’s proven expertise in mission-critical software and complex system integration with Heron’s end-to-end BNCT platforms, the partnership aims to drive broader global clinical adoption of this highly targeted cancer treatment modality.
Article content
Article content
Article content
“AB-BNCT is emerging as one of the most promising approaches for treating difficult-to-treat and recurrent cancers,” said Mark Pleško, Chief Executive Officer of Cosylab. “This collaboration reinforces our strategic focus on advancing radiation therapy technologies and expanding our reach in the Asia-Pacific region and beyond. We are committed to delivering impactful joint projects with Heron that accelerate market readiness and clinical adoption.”
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“This agreement represents a key step in Heron’s international growth strategy,” underlined Shen Hsiao-Lien, General Manager of Heron Neutron Medical Corp. “Working with Cosylab will strengthen our cross-regional capabilities and support the rapid scaling of AB-BNCT solutions in markets worldwide.”
Article content
About Cosylab:
Article content
Cosylab (
Article content
Article content
) develops software and control systems for the world’s most demanding scientific and medical technology environments, including particle accelerators, radiation therapy systems, fusion research facilities, and semiconductor equipment. Founded in 2001 and headquartered in Ljubljana, Slovenia, Cosylab operates globally across research institutions, hospitals, and industrial facilities.
Article content
About Heron Neutron Medical Corp.:
Article content
Heron Neutron Medical Corp. develops integrated Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems that encompass accelerator technologies, neutron beamlines, treatment platforms, and full clinical workflow integration. The company is dedicated to advancing innovative cancer treatment solutions and expanding global access to BNCT.
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Contacts
Article content
Contact (Cosylab): Petra Balažic, [email protected]
Article content
English (US)